---
company: Rapport Therapeutics, Inc.
ticker: RAPP
form: 8-K
filed: 2026-10-30
accepted: 2026-10-30T21:12:36+00:00
accession: 0001193125-26-441851
source: https://www.sec.gov/Archives/edgar/data/2012593/000119312526441851/
---

# Rapport Therapeutics (RAPP) Q3 2026 earnings

## Header

- Company: Rapport Therapeutics, Inc.
- Reported: 2026-10-30 17:12 AMC ET
- Source: 8-K only — accession 0001193125-26-441851, Item 2.02 + Exhibit 99.1
- Verdict: Net loss widened to $56.6 million as R&D expenses increased to $51.4 million, though cash position remained strong at $436.1 million.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---:|---|---|
| EPS (GAAP) | -$1.19 | +59% | — | Ex. 99.1, income statement |

## Revenue breakdown

not stated in the 8-K

## Margins and costs

- Gross margin: not stated in the 8-K
- Operating expenses: $60.8 million (+106% YoY)
- One-offs in the quarter: not stated in the 8-K
- Effective tax rate: not stated in the 8-K
- Non-GAAP bridge: not stated in the 8-K

## KPIs

not stated in the 8-K

## Guidance

not stated in the 8-K

## What drove it

- Revenue story: No revenue reported; company is clinical-stage.
- EPS story: Net loss per share widened to -$1.19 driven by higher operating expenses.
- One-off check: not stated in the 8-K

## The good

- Cash position of $436.1 million expected to fund operations into the second half of 2029

## The bad

- Net loss widened to $56.6 million (+112% YoY)
- R&D expenses increased to $51.4 million (+127% YoY)
- SG&A expenses increased to $9.4 million (+38% YoY)

## The ugly

- none

## Open questions

- No Q3 financial results were provided in the filing; only a business update was attached.

## Full release

### Rapport Therapeutics (RAPP) earnings release, October 30, 2026

Rapport Therapeutics, Inc. (RAPP) · Form 8-K, Item 2.02 · Filed 2026-10-30 · [SEC filing](https://www.sec.gov/Archives/edgar/data/2012593/000119312526441851/)

No press release attached to this 8-K.
